Analysts reiterated their buy call on $ARRY stock. The company reported clinical results for its colorectal cancer drug. Life expectancyrose to 8.4 months. Despite the uneven clinical results, markets took the stock ~25% higher. Source: tipranks.com Analyst Rating PT 3.2 Buy $34 Cantor Fitzgerald 4.5 Buy $32 SunTrust Robinson 4.4 Buy 35 Piper Jaffray 3.4 Buy $25 Cowen & Co. Watch Arry stock in the coming days.